TSE:MSL - Merus Labs International Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseC$1.64
Today's RangeC$1.64 - C$1.65
52-Week RangeC$0.95 - C$1.76
Volume21,975 shs
Average Volume476,228 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Merus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company's products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates. Sintrom is an anticoagulant indicated to treat and prevent thromboembolic diseases. Emselex/Enablex is used in adults to treat overactive bladder syndrome. Surgestone is used to treat women with menstrual irregularities due to ovulation disorder, dysmenorrhea and premenstrual syndrome. Provames is used as hormone replacement therapy in postmenopausal women with symptoms of estrogen deficiency.

Receive MSL News and Ratings via Email

Sign-up to receive the latest news and ratings for MSL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
Phone+1-905-7260995

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
OptionableNot Optionable

Merus Labs International (TSE:MSL) Frequently Asked Questions

What is Merus Labs International's stock symbol?

Merus Labs International trades on the Toronto Stock Exchange (TSX) under the ticker symbol "MSL."

Has Merus Labs International been receiving favorable news coverage?

News coverage about MSL stock has been trending negative on Thursday, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Merus Labs International earned a coverage optimism score of -2.0 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the next few days.

Who are Merus Labs International's key executives?

Merus Labs International's management team includes the folowing people:
  • Michael S. Cloutier, Independent Chairman of the Board
  • Barry Fishman, Chief Executive Officer, Director
  • Michael Scott Bumby, Chief Financial Officer
  • Robert McLay, Vice President - Sales and Marketing
  • Frank Rotmann, Vice President and Head of European Operations
  • Robert Bloch M.D., Director
  • Theresa Sheila Firestone, Independent Director
  • David D. Guebert CPA, Independent Director
  • Robert S. Pollock, Independent Director
  • Timothy G. Sorensen, Independent Director

How do I buy shares of Merus Labs International?

Shares of MSL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Merus Labs International's official website?

The official website for Merus Labs International is http://www.meruslabs.com/.

How can I contact Merus Labs International?

Merus Labs International's mailing address is 100 Wellington St. West Suite 2110 Stn Toronto Dom PO Box 151, TORONTO, ON M5K 1H1, Canada. The specialty pharmaceutical company can be reached via phone at +1-905-7260995.


MarketBeat Community Rating for Merus Labs International (TSE MSL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  214 (Vote Outperform)
Underperform Votes:  159 (Vote Underperform)
Total Votes:  373
MarketBeat's community ratings are surveys of what our community members think about Merus Labs International and other stocks. Vote "Outperform" if you believe MSL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MSL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel